Sophiris Bio, Inc.
SPHS
SPHS was delisted on the 11th of March, 2020.
24 hedge funds and large institutions have $40.6M invested in Sophiris Bio, Inc. in 2013 Q3 according to their latest regulatory filings, with 24 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
53.95% more ownership
Funds ownership: 0% → 53.95% (+54%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.44M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.6M |
| 3 |
First Manhattan
New York
|
+$4.61M |
| 4 |
AG
Artal Group
Luxembourg
|
+$4.61M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$2.77M |
Top Sellers
SPHS Hedge Fund Activity: Q3 2013 in Review
24 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Sophiris Bio, Inc. (SPHS) for Q3 2013, worth a combined $40.6M.
Buyers outnumbered sellers: 24 funds opened new SPHS positions and 0 closed out — a net gain of 24 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $7.44M.
- 24 institutional investors held Sophiris Bio, Inc. (SPHS) as of Q3 2013, up from 0 in Q2 2013.
- Funds reported $40.6M of Sophiris Bio, Inc. stock for Q3 2013.
- 24 funds opened new Sophiris Bio, Inc. positions in Q3 2013 and 0 closed out, a net change of +24 holders.
- The largest Sophiris Bio, Inc. buyer in Q3 2013 was T. Rowe Price Associates, an estimated $7.44M added.
Based on aggregated 13F filings for Q3 2013.